Recent progress in shigella and burkholderia pseudomallei vaccines

Itziar Chapartegui-González, Sarah Bowser, Alfredo G. Torres, Nittaya Khakhum

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Significant advancement has been made in the development of vaccines against bacterial pathogens. However, several roadblocks have been found during the evaluation of vaccines against intracellular bacterial pathogens. Therefore, new lessons could be learned from different vaccines developed against unrelated intracellular pathogens. Bacillary dysentery and melioidosis are important causes of morbidity and mortality in developing nations, which are caused by the intracellular bacteria Shigella and Burkholderia pseudomallei, respectively. Although the mechanisms of bacterial infection, dissemination, and route of infection do not provide clues about the commonalities of the pathogenic infectious processes of these bacteria, a wide variety of vaccine platforms recently evaluated suggest that in addition to the stimulation of antibodies, identifying protective antigens and inducing T cell responses are some additional required elements to induce effective protection. In this review, we perform a comparative evaluation of recent candidate vaccines used to combat these two infectious agents, emphasizing the common strategies that can help investigators advance effective and protective vaccines to clinical trials.

Original languageEnglish (US)
Article number1353
Issue number11
StatePublished - Nov 2021


  • Burkholderia pseudomallei
  • Glycoconjugate vaccines
  • Live attenuated
  • Shigella
  • Subunit vaccines
  • Vaccines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Molecular Biology
  • General Immunology and Microbiology
  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Recent progress in shigella and burkholderia pseudomallei vaccines'. Together they form a unique fingerprint.

Cite this